BUSINESS
    Sanofi Japan Introduces 2-Week-Rule before Getting Back to Full Operations after COVID-19 Emergency Lift
    May 29, 2020
    Japan’s pharma industry is resuming its operations after the lifting of the country’s state of emergency declaration. The Japan arm of Sanofi has introduced a rule under which its reps continue to work from home…

    LATEST

    Otsuka’s Q1 Pharma Sales Surge 13% on Global Brands
    May 29, 2020
    Otsuka Holdings’ pharmaceutical revenue in the first quarter of 2020 grew over 13%, driven by four global brands including the selective vasopressin V2 receptor antagonist tolvaptan and the antipsychotic Abilify Maintena (aripiprazole), according to its earnings released on May 28.In…
    MHLW Panel Gives Blessing to 1st Triple Combo Therapy for Asthma; Humira Biosimilar Also in Line for June OK
    May 29, 2020
    A key health ministry advisory panel on May 28 cleared Novartis’ asthma drug known as Enerzair, which will be the first triple combination inhaled therapy for the disease, along with a batch of other medicines. If all goes well, they…
    JPWA Resolution Urges Govt to Revisit Off-Year Drug Re-Pricing
    May 29, 2020
    The Federation of Japan Pharmaceutical Wholesalers Associations (JPWA) on May 28 adopted a resolution leaning on the government to revisit its plan to conduct so-called “off-year” drug re-pricing, beginning in April 2021, in view of the current COVID-19 crisis.In the…

    COMMENTARY

    Establish Development Regime to Always Be Prepared for New Infectious Disease, Global Health Confab Urges amid COVID-19
    By Kazuhiro Chiboshi

    The Executive Committee on Global Health and Human Security has compiled draft proposals to further promote pharmaceutical and medical device regulatory harmonization in Asia. While the proposals revolve around initiatives for two main pillars - building clinical trial networks and…

    Post-Promotion Guidelines

    Post-Promotion Guidelines - 2: Takeda Evaluating “Non-Sales” Factors through Quality Conversations with Bosses
    By Takamitsu Sasai

    When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…

    INTERVIEW

    Improper Materials Apparently Decreased after Promotion Guidelines Introduced: Pharmacist
    By Takamitsu Sasai

    Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…

    Impact of Oligonucleotides

    Impact of Oligonucleotides - 3: Advances in Modified Oligo Technologies Pave Way for Innovative Drug Arrivals
    By Takashi Ebisawa

    Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…

    FY2020 Drug Pricing Reform

    Japan Panel Hammers Out FY2020 Drug Pricing Reform

    Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

    Reimbursement Listing in 2018-2019

    Japan’s First Biosimilars of Avastin, Nesp, Forteo Receive Listing

    The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…

    TRENDS

    51 Drugs Listed in 2019 with Total Peak Sales Forecast of 370 Billion Yen, Many for Orphan Diseases

    A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…

    My Viewpoint on CEA

    Ensuring Patient Access Was MHLW’s Top Priority for CEA Scheme: Policy Planning Director
    By Yoshinori Sagehashi

    Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

    HTA Debates in 2018-2019

    Japan to Roll Out Cost-Effectiveness Assessment Scheme in April

    Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

    COLUMN

    Smart Strategies for Building Your Dream Team
    By Philip Carrigan

    Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA